The prostate cancer market was valued at USD 13.48 Billion in 2025 and is expected to grow at a CAGR of 9.20%, reaching USD 32.50 Billion by 2035. The market growth is driven by rising disease prevalence, expanding treatment innovations, and increasing adoption of advanced diagnostic technologies across the 8 major markets.
Base Year
Historical Period
Forecast Period
AstraZeneca’s acquisition of Fusion Pharmaceuticals strengthened radiopharmaceutical innovation, accelerated next-generation treatment development, and reshaped advanced prostate cancer care through a more robust and future-ready therapeutic pipeline.
FDA authorization of an AI risk-stratification tool marked a clear shift toward intelligent diagnostics, enabled earlier detection, improved clinical decision-making, and boosted confidence in technology-driven care pathways.
EU approval of Darolutamide’s third indication expanded treatment flexibility, enhanced advanced disease management, and supported broader access to effective therapies across regions experiencing increasing prostate cancer treatment needs.
Compound Annual Growth Rate
9.2%
Value in USD Billion
2026-2035
*this image is indicative*
The market continues to grow steadily as rising disease prevalence, better screening awareness, and rapid adoption of innovative therapies reshape the treatment landscape. Advancements in diagnostics, expanding treatment indications, and strong regulatory support are enabling earlier detection and more personalized care. Investments, strategic acquisitions, and technological innovations are further accelerating progress, creating broader opportunities for healthcare providers and industry players. With improvements across treatment, diagnostics, and care delivery, the overall outlook for the market remains strong, supported by active research, expanding pipelines, and increasing global demand for effective solutions.
Rising Disease Prevalence Bolstering the Market Value
The increasing disease prevalence is expected to be a major growth driver in the market, creating a stronger push for advanced screening and treatment solutions. For example, in May 2025, the American Cancer Society reported that the United States may witness about 313,780 new prostate cancer cases, reflecting how rapidly the patient pool is expanding. This steady rise also highlights how early detection and timely intervention are becoming essential priorities for both patients and providers. As the burden continues to grow, the demand for innovative diagnostics, precision therapies, and comprehensive care models is increasing significantly. As a result, interest in the market is accelerating across the U.S., further strengthening overall market momentum.
Rise in Strategic Acquisitions Accelerating the Prostate Cancer Market Value
Growing strategic activity is expected to be a major growth driver in the market, creating stronger interest in advanced and innovative cancer solutions. For instance, in March 2024, AstraZeneca announced its plan to acquire Fusion Pharmaceuticals for up to USD 2.4 billion. This significant move shows how major players are accelerating their focus on cutting-edge radiopharmaceutical technologies to strengthen future treatment pipelines. The acquisition also reflects rising confidence in radioligand therapies as a promising direction in oncology. With investment flowing toward innovation, momentum in the prostate cancer therapies market continues to intensify, supporting long-term market expansion.
The market is witnessing several emerging trends, including broader treatment approvals, rapid adoption of AI-driven diagnostics, and growing focus on precision-based prostate cancer care.
Increasing Regulatory Momentum to Boost the Prostate Cancer Market Growth
A growing shift toward advanced and technology-driven diagnostics is emerging as a key trend in the market. For instance, in August 2025, the U.S. Food and Drug Administration granted de-novo authorization for an AI-powered risk-stratification tool for non-metastatic prostate cancer and accepted a new filing for a PSMA-PET imaging agent. These developments show how smarter diagnostic pathways are becoming an industry priority, strengthening confidence in innovation. As regulatory support increases, interest in the prostate cancer treatment market continues to rise, reinforcing the move toward more precise and efficient care solutions.
Growing Expansion of Treatment Indications to Propel the Prostate Cancer Market Demand
Steady growth in broader treatment approvals is shaping an important trend in the market. For example, in July 2025, Bayer announced that Darolutamide (Nubeqa™) received EU approval for its third indication, expanding its use for patients with metastatic hormone-sensitive prostate cancer. This development also reflects how regulatory bodies are increasingly supporting therapies that deliver proven clinical value. As therapeutic choices continue to widen, clinicians gain more room to provide personalized and effective care. With more treatments gaining extended approvals, momentum continues to build, reinforcing the market’s shift toward advanced and accessible treatment options.
Technology-Driven Diagnostic Innovations are Poised to Accelerate the Prostate Cancer Market Value
Growing emphasis on intelligent diagnostic tools is gradually becoming a notable trend in the market. For instance, in November 2025, NHS hospitals announced that they will begin piloting an AI tool designed to analyze prostate biopsies and guide treatment decisions for thousands of patients. This initiative reflects how healthcare systems are increasingly embracing advanced technologies to improve diagnostic speed and accuracy. The move also highlights growing confidence in digital tools that support clinicians in making more informed decisions. As AI solutions become more integrated into routine care, interest in the market continues to rise, strengthening the shift toward earlier and more personalized detection.
Hormonal Therapy Expected to Lead the Market Share by Treatment
Hormonal therapy is expected to lead the treatment segment, mainly because it remains the most widely adopted and effective first-line option for managing prostate cancer across various stages. Its strong clinical success, broad patient suitability, and continuous improvements in androgen-targeted drugs keep it at the center of treatment decisions. This leadership position also reflects the growing preference for therapies that offer predictable outcomes and are easier to integrate into routine care. As demand for reliable and accessible solutions increases, hormonal therapy continues to drive overall market growth. Other key treatments include chemotherapy, immunotherapy, targeted therapy, and radiopharmaceuticals.
The United States is expected to lead this market due to its strong healthcare spending, rapid adoption of advanced therapies, and a large patient base that consistently drives demand for improved diagnostic and treatment solutions. This leadership is further strengthened by a mature innovation ecosystem where companies, research bodies, and regulators work closely to accelerate progress. As investments continue to support new technologies and precision-based approaches, the country remains at the forefront of market development. The second-ranking region is Europe, where strong healthcare systems and increasing access to modern therapies continue to support steady market expansion.
The key features of the market report comprise clinical trials and pipeline analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson (Janssen) has remained a major force in advancing prostate cancer treatments. Over the years, the company has built a strong oncology footprint backed by high-quality research and long-term clinical expertise. Its continued investments in next-generation androgen pathway inhibitors and targeted therapies have helped reshape how advanced prostate cancer is managed. By focusing on innovation and patient outcomes, Janssen continues to play a defining role in this market.
Founded in 1849 and headquartered in New York City, Pfizer has established a strong presence in the oncology space through its expanding portfolio of targeted cancer therapies. The company’s long-term commitment to scientific research allows it to introduce treatment options that address evolving disease patterns and patient needs. Strategic partnerships and a robust clinical pipeline further support its efforts to enhance therapeutic outcomes. Through these advancements, Pfizer continues to contribute meaningfully to progress within the prostate cancer market.
Established in 2005 and headquartered in Tokyo, Japan, Astellas Pharma has steadily strengthened its influence in urologic oncology with innovative therapies designed for complex stages of prostate cancer. The company’s focus on research-driven development enables it to deliver solutions that enhance treatment precision and effectiveness. Ongoing collaborations and global clinical programs support its broader mission to improve patient access to modern care. Through these efforts, Astellas continues to shape meaningful advancements in this industry.
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer remains an important contributor to the prostate cancer market through its advancements in radiopharmaceuticals and targeted therapies. The company’s science-backed approach allows it to introduce therapies that address unmet needs, particularly in advanced disease stages. Continuous development of new indications and strong clinical evidence further enhance its impact on treatment evolution. With ongoing investments in next-generation technologies, Bayer continues to support long-term progress across the prostate cancer treatment landscape.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Novartis AG, Sanofi, Ipsen Pharma, and AstraZeneca.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Stage
Market Breakup by Treatment
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Country
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Stage |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share